Tsubota Laboratory Incorporated
4890.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.71B
Close$
$13.27
94.9% downside
Current Fair Value
94.9% downsideOvervalued by 94.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.71 Billion |
|---|---|
| Enterprise Value | $6.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-29.58 |
| Beta | 1.16 |
| Outstanding Shares | 25,794,300 |
Return
| Return on Equity | -94.52% |
|---|---|
| Return on Assets | -52.85% |
| Return on Invested Capital | -95.36% |
Valuation & Multiples
| P/E Ratio | -9.67 |
|---|---|
| PEG | 28.68 |
| Price to Sales | 17.33 |
| Price to Book Ratio | 9.29 |
| Enterprise Value to Revenue | 16.07 |
| Enterprise Value to EBIT | -8.49 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tsubota Laboratory Incorporated
22 employees
CEO: Kazuo Tsubota Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.